TWST Form 4: CFO now beneficially owns 143,656 company shares

Rhea-AI Filing Summary

Twist Bioscience Corp (TWST) reported that its Chief Financial Officer received a grant of 32,648 restricted stock units (RSUs) of common stock on 11/18/2025. The RSUs were recorded at a price of $0 because they are equity awards rather than open‑market purchases.

Following this grant, the CFO beneficially owns 143,656 shares of Twist Bioscience common stock in total. The RSU award vests over four years: 1/16 of the total RSUs vest on each quarterly anniversary of November 20, 2025, for a total vesting period of 48 months, as long as the executive remains in continuous service through each vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Laponis Adam

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	32,648	$0.00	--

Holdings After Transaction: Common Stock — 143,656 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Laponis Adam

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/18/2025		A		32,648(1)	A	$0	143,656	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a restricted stock unit award ("RSU") of which 1/16th of the total number of RSUs vest on each quarterly anniversary of November 20, 2025 for a total vesting period of 48 months, subject to the Reporting Person's continuous service through each vesting date.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Adam Laponis	11/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity award did Twist Bioscience (TWST) grant to its CFO?

The Chief Financial Officer received a restricted stock unit (RSU) award of 32,648 shares of Twist Bioscience common stock.

When do the new RSUs for Twist Bioscience (TWST) CFO start vesting?

The RSUs begin vesting on the quarterly anniversaries of November 20, 2025, with installments every quarter.

What is the vesting schedule for the 32,648 Twist Bioscience (TWST) RSUs?

1/16 of the 32,648 RSUs vests on each quarterly anniversary of November 20, 2025, over a 48‑month total vesting period, subject to continuous service.

How many Twist Bioscience (TWST) shares does the CFO beneficially own after this transaction?

After the reported RSU grant, the CFO beneficially owns 143,656 shares of Twist Bioscience common stock.

Was cash paid for the Twist Bioscience (TWST) CFO’s RSU grant?

The Form 4 lists the transaction price as $0, reflecting that this was an equity award rather than a market purchase.

Is the Twist Bioscience (TWST) CFO filing a joint Form 4 with others?

No. The Form 4 is indicated as filed by one reporting person, covering only the CFO.